Why Is Natera Stock Up Nearly 41% Since May?

Natera (NTRA) stock rose 40.8% from May 20 to November 16, 2026, driven by strong revenue growth and raised forecasts. The company reported Q2 revenue of $752.8M (up 37.7% YoY) and Q3 revenue of $794M (up 34.1% YoY), with a narrowed operating loss margin. Natera also gained in organ transplant testing due to Medicare coverage. The stock's performance outpaced the S&P 500, which gained 0.3% over the same period.

Original reporting
Published Nov 17, 2026, 11:29 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 11:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Why Is Natera Stock Up Nearly 41% Since May? — source image
Decision brief

The 30-second read

$NTRABullishMed
01

Why it matters

The piece links the rally to strong revenue growth and a higher full-year forecast, plus Medicare coverage taking effect for transplant monitoring, while emphasizing that profitability depends on operating-margin progress.

02

Market read

Traders get a catalyst map for Natera’s move: revenue growth, raised guidance, narrowing operating losses, and the next operating-margin inflection expected in February 2027.

03

What to watch

Operating margin is flagged as the next key metric, so investors may be underweighting execution risk toward profitability despite revenue growth and forecast raises.

Relevance 6/10Novelty 5/10Timing: ahead of the next report expected in February 2027

Background

Natera sells DNA tests for cancer care, prenatal care, and organ transplants, and the article explains the stock’s ~41% rise since May alongside two quarterly updates.

Company-level read

Ticker impact

$NTRABullishHigh confidence
Context

Natera shares surged after its Nov. 5 report raised the full-year revenue forecast to above $3B and set a 2029 $6B goal.

Expected impact

Near-term bias remains upward on continued execution, but volatility risk persists given the prior selloff after the second report and the next operating-margin checkpoint.

Evidence & confidence

The article attributes the multi-month rally to two quarterly reports, with the Nov. 5 forecast raise as the key catalyst, while also flagging that the next report’s operating margin is the key metric.

Market effects

Reinforces investor appetite for profitable momentum in molecular diagnostics and cancer/prenatal testing, especially where reimbursement expands.

Primarily US-listed growth-stock sentiment, with limited direct regional spillover beyond healthcare diagnostics.

Moderate, as reimbursement-driven demand and margin trajectory are globally relevant themes for diagnostic providers.

Counterpoint

The article’s own timeline shows the stock jumped after the Aug. 6 report but fell after the Nov. 5 report, suggesting the market may be trading expectations rather than fundamentals.

Key entities

  • Natera

    DNA testing company whose quarterly reports and guidance changes drove the stock’s multi-month move.

  • Labcorp

    Mentioned as a comparison point for stock performance over the same period.

Related articles

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.

$NTRAMedAI 8/10

NTRA Q3 Loss Wider Than Expected, Revenues Beat, '26 Sales View Up

Natera reported a Q3 2026 adjusted loss of 39 cents per share, wider than expected, but revenues of $794M beat estimates. Oncology and women's health drove growth, with total tests up 34.1% YoY. The company raised 2026 revenue guidance to $3.005B-$3.035B. Gross margin improved, but operating loss narrowed. Cash flow remained positive.